

Title: Dermatology and Respiratory Medicine

Reference Number: RDF1439-23

Date of Response: 27/04/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:

1. Q1. *How many patients were treated in March 2023 (or latest available month) by the Dermatology department with the following drugs:*

- *Abrocitinib (Cibinqo)*
- *Baricitinib (Olumiant)*
- *Dupilumab (Dupixent)*
- *Omalizumab (Xolair)*
- *Tralokinumab (Adtralza)*
- *Upadacitinib (Rinvoq)*

Answer: Please see table below. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

<i>Drug treatment</i>	<i>Royal Devon No. of Patients treated</i>
<i>Abrocitinib (Cibinqo)</i>	≤ 5
<i>Baricitinib (Olumiant)</i>	≤ 5
<i>Dupilumab (Dupixent)</i>	≤ 5
<i>Omalizumab (Xolair)</i>	37

<i>Tralokinumab (Adtralza)</i>	≤5
<i>Upadacitinib (Rinvoq)</i>	6

2. Q2. How many patients were treated in March 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:

- *Benralizumab (Fasenra)*
- *Dupilumab (Dupixent)*
- *Mepolizumab (Nucala)*
- *Omalizumab (Xolair)*
- *Reslizumab (Cinqaero)*
- *Tezepelumab (Tezspire)*

Answer: Please see table below.

<i>Drug treatment</i>	<i>Royal Devon No. of Patients treated</i>
<i>Benralizumab (Fasenra)</i>	51
<i>Dupilumab (Dupixent)</i>	7
<i>Mepolizumab (Nucala)</i>	17
<i>Omalizumab (Xolair)</i>	31
<i>Reslizumab (Cinqaero)</i>	Nil
<i>Tezepelumab (Tezspire)</i>	≤5